

1 **Title: Anxiety disorders and age-related changes in physiology**

2

3 **Short title:** Physiological changes in anxiety disorders

4

5 **Authors:** Julian Mutz^{1*}, Thole H. Hoppen², Chiara Fabbri^{1,3} and Cathryn M. Lewis^{1,4}

6

7 **Affiliations:**

8 1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
9 Neuroscience, King's College London, London, United Kingdom.

10 2. Institute of Psychology, University of Münster, Münster, Germany.

11 3. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

12 4. Department of Medical and Molecular Genetics, Faculty of Life Sciences & Medicine, King's
13 College London, London, United Kingdom.

14

15 ***Corresponding author:**

16 Julian Mutz; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,

17 Psychology & Neuroscience, King's College London, Memory Lane, London SE5 8AF, United

18 Kingdom. Email: julian.mutz@gmail.com.

19 **Abstract**

20 **Background:** Anxiety disorders are leading contributors to the global disease burden, highly prevalent
21 across the lifespan, and associated with substantially increased morbidity and early mortality.

22 **Aims:** The aim of this study was to examine age-related changes across a wide range of physiological
23 measures in middle-aged and older adults with a lifetime history of anxiety disorders compared to
24 healthy controls.

25 **Method:** The UK Biobank study recruited >500,000 adults, aged 37–73, between 2006–2010. We used
26 generalised additive models to estimate non-linear associations between age and hand-grip strength,
27 cardiovascular function, body composition, lung function and heel bone mineral density in cases and in
28 controls.

29 **Results:** The main dataset included 332,078 adults (mean age = 56.37 years; 52.65% females). In both
30 sexes, individuals with anxiety disorders had a lower hand-grip strength and blood pressure, while their
31 pulse rate and body composition measures were higher than in healthy controls. Case-control
32 differences were larger when considering individuals with chronic and/or severe anxiety disorders, and
33 differences in body composition were modulated by depression comorbidity status. Differences in age-
34 related physiological changes between female anxiety disorder cases and healthy controls were most
35 evident for blood pressure, pulse rate and body composition, while in males for hand-grip strength,
36 blood pressure and body composition. Most differences in physiological measures between cases and
37 controls decreased with increasing age.

38 **Conclusions:** Individuals with a lifetime history of anxiety disorders differed from healthy controls
39 across multiple physiological measures, with some evidence of case-control differences by age. The
40 differences observed varied by chronicity/severity and depression comorbidity.

41

42 **Keywords:** Ageing; Anxiety; Body composition; Cardiovascular function; Physiology

43 **Introduction**

44

45 Anxiety disorders are leading contributors to the global disease burden, highly prevalent across the
46 lifespan and across nations, and associated with substantially increased morbidity and early mortality(1-
47 4). A population-based study from Denmark reported that individuals with anxiety disorders had a 39%
48 higher risk of premature death than the general population(5). This excess mortality does not result only
49 from unnatural causes of death such as suicide, but also from increased rates of dementia, cardiovascular
50 disease and other illnesses. Anxiety disorders are also associated with accelerated biological ageing,
51 including earlier neurodegeneration(6, 7) and telomere attrition(8, 9), and an increased risk of disability
52 in old age, especially in individuals with comorbid depression(10, 11). Less is known about
53 physiological differences between individuals with anxiety disorders and healthy controls, and whether
54 such differences vary by age. A Dutch longitudinal study reported that individuals with anxiety
55 disorders had poorer lung function than healthy controls, and that men with anxiety disorders showed
56 a greater decline in lung function over time(12). Women with anxiety disorders also had a lower hand-
57 grip strength. More severe anxiety disorders were associated with greater physiological abnormalities.
58 Most studies of physiology in anxiety disorders have focussed on one or two physiological
59 measures(12-14) and research examining a range of physiological measures is lacking. To the best of
60 our knowledge, this is the first study to examine age-related changes across a wide range of
61 physiological measures in middle-aged and older adults with anxiety disorders. Most physiological
62 measures can be assessed non-invasively, fast and at low cost, while providing reliable information on
63 functional decline. Importantly, variation in physiological functioning predicts morbidity and mortality.
64 A greater understanding of age-related physiological changes in anxiety disorders may inform strategies
65 for prevention and intervention to foster healthy ageing.

66

67 **Aims**

68 The aim of this cross-sectional study was to examine associations between age and 15 physiological
69 markers in individuals with a lifetime history of anxiety disorders compared to healthy controls. Since
70 the epidemiology of anxiety disorders(2) and human physiology(15) differ by sex, we conducted
71 separate analyses in males and females. Given that a dose-response relationship between anxiety
72 disorder severity and differences in physiology has been reported before(12), we also examined chronic
73 and/or severe anxiety disorders. Finally, depression has been associated with age-related changes in
74 physiology(16) and is highly comorbid with anxiety disorders(2-4, 12), hence we also examined
75 individuals with anxiety disorders without comorbid depression.

76

77 **Method**

78

79 **Study population**

80 The UK Biobank is a prospective study of >500,000 adults aged 37–73 at baseline, recruited between
81 2006–2010. The study rationale and design have been described elsewhere(17). Briefly, individuals
82 registered with the UK National Health Service (NHS) and living within a ~40 km radius of one of 22
83 assessment centres were invited to participate. Participants provided information on their
84 sociodemographic characteristics, lifestyle and medical history and underwent physical examination.
85 Hospital inpatient records are available for most participants and primary care records are currently
86 available for half of participants. A subset of 157,366 out of 339,092 invited participants (46%)
87 completed an online follow-up mental health questionnaire (MHQ) between 2016 and 2017, covering
88 31% of all participants.

89

90 **Exposures**

91 Age at the baseline assessment was the primary explanatory variable.

92

93 Details of the definition of cases and healthy controls are presented in [Supplement 1](#). Briefly, we used
94 a transdiagnostic phenotype for lifetime anxiety disorders and identified cases from multiple sources:
95 the generalised anxiety disorder module of the Composite International Diagnostic Interview Short
96 Form (CIDI-SF) ([Supplement 2](#))(18) and the Generalised Anxiety Disorder Assessment (GAD-7)(19),
97 which were assessed through the MHQ; psychiatric diagnoses reported during the nurse-led interview
98 at baseline or in the MHQ; hospital inpatient records ([Supplement 3](#)); primary care records(20)
99 ([Supplement 4](#)). We excluded individuals with bipolar disorder or psychosis, as these disorders are
100 strongly associated with the risk of physical multimorbidity(21, 22). Healthy controls had no anxiety
101 disorders, reported no current psychotropic medication use at baseline ([Supplement 5](#))(23) and had no
102 other mental disorders: no psychiatric diagnosis according to the nurse-led interview, MHQ, hospital
103 inpatient or primary care records; no probable mood disorder(24) ([Supplement 6](#)); no Patient Health
104 Questionnaire-9 (PHQ-9) sum score of ≥ 5 ; no GAD-7 sum score of ≥ 5 ; did not report ever feeling
105 worried, tense, or anxious for most of a month or longer; no depression or bipolar disorder based on the
106 CIDI-SF depression module and questions on (hypo)manic symptoms(16, 25).

107

108 **Physiological measures**

109 We examined 15 physiological measures obtained at the baseline assessment, including maximal hand-
110 grip strength, systolic and diastolic blood pressure, pulse rate, body mass index (BMI), waist-hip ratio,
111 fat mass, fat-free mass, body fat percentage, peak expiratory flow, forced vital capacity (FVC), forced
112 expiratory volume in one second (FEV₁), FVC/FEV₁ ratio, heel bone mineral density and arterial

113 stiffness. Details of these measures have previously been reported in our study on age-related
114 physiological changes in depression(16) and are presented in [Supplement 7](#).

115

116 **Exclusion criteria**

117 Participants whose genetic and self-reported sex did not match and participants with missing data,
118 including “do not know” or “prefer not to answer”, for any covariates were excluded.

119

120 **Covariates**

121 Covariates were identified from previous studies and included ethnicity, highest
122 educational/professional qualification(26), physical activity (walking, moderate and vigorous-intensity
123 activity), smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures,
124 antihypertensive medication use (fields 6153 and 6177). Details of the sociodemographic and lifestyle
125 factors are available in our previous publication(27).

126

127 **Statistical analyses**

128 Analyses were prespecified prior to inspection of the data (preregistration: osf.io/hqu2f) and algorithms
129 were tested on simulated data. Statistical analyses were conducted using R (version 3.6.0).

130

131 Sample characteristics were summarised using means and standard deviations or counts and
132 percentages. Case-control differences were estimated using standardised mean differences (\pm 95%
133 confidence intervals).

134

135 We examined the relationship between each physiological measure and age using generalised additive
136 models (GAMs) with the ‘mgcv’ package in R(28). GAMs are flexible modelling approaches that allow
137 for the relationship between an outcome variable and a continuous exposure to be represented by a non-
138 linear smooth curve while adjusting for covariates. This approach is useful if a linear model does not
139 capture key aspects of the relationship between variables and attempts to achieve maximum goodness-
140 of-fit while maintaining parsimony of the fitted curve to minimize overfitting. Smoothing parameters
141 were selected using the restricted maximum likelihood method and we used the default option of ten
142 basis functions to represent smooth terms. Each measure was modelled against a penalised regression
143 spline function of age with separate smooths for anxiety disorder cases and healthy controls.

144

145 Two models were fitted for each physiological measure in males and females separately:

146

- 147 • Unadjusted model: physiological measure \sim anxiety disorder + s(age, by anxiety disorder).
- 148 • Adjusted model: physiological measure \sim anxiety disorder + s(age, by anxiety disorder) +
149 covariates (see previous paragraph).

150

151 where $s(\text{age, by anxiety disorder})$ represents the smooth function for age, stratified by anxiety disorder
152 status.

153

154 To formally test whether the relationships between physiological measures and age differed between
155 anxiety disorder cases and controls, we also fitted models that included reference smooths for healthy
156 controls and difference smooths for anxiety disorder cases compared to healthy controls. For these
157 analyses, anxiety disorder status was coded as an ordered factor in R. If the difference smooth differs
158 from zero, the physiological measure follows a different trend with age in anxiety disorder cases and
159 healthy controls.

160

161 Adjusted p -values were calculated using the $p.adjust$ function in R to account for multiple testing across
162 each set of analyses of the 15 physiological measures. Two methods were used: (1) Bonferroni and (2)
163 Benjamini & Hochberg(29), two-tailed with $\alpha = .05$ and false discovery rate of 5%, respectively. We
164 have opted for this approach because the standard Bonferroni correction is usually too conservative,
165 potentially leading to a high number of false negatives.

166

167 In a secondary analysis, we examined individuals with chronic and/or severe anxiety disorders, defined
168 as individuals with (i) a hospital inpatient record of anxiety disorders as the primary diagnosis, (ii)
169 recurrent or chronic anxiety (E2004 or E2005) in their primary care record or (iii) generalised anxiety
170 disorder according to the CIDI-SF with maximum level of impairment (“Impact on normal roles during
171 worst period of anxiety” (field 20418) = A lot) and duration (“Longest period spent worried or
172 anxious” (field 20420) = All my life / as long as I can remember or at least 24 months).

173

174 In a sensitivity analysis, we excluded individuals with depression comorbidity from anxiety disorder
175 cases(16).

176

177 We conducted two additional sensitivity analyses that were not pre-registered: (i) we additionally
178 adjusted analyses of cardiovascular measures for BMI and (ii) we excluded anxiety disorder cases who
179 reported current use of antidepressants at baseline from the analyses of blood pressure.

180 Results

181

182 Study population

183 A subset of 444,690 (88.49%) participants had complete data on all covariates. After excluding
184 participants with missing physiological data, unclear anxiety disorder status ($n = 93$) or not meeting
185 our inclusion criteria, we retained 332,078 participants in the main dataset. Subsets of 123,597, 228,321
186 and 107,958 participants were included in the analyses of lung function, heel bone mineral density and
187 arterial stiffness, respectively (Supplement Figure 1).

188 Sample characteristics

189 The average participant age in our main dataset was 56.37 years (SD = 8.11) and 52.65% of
190 participants were female. Overall, 44,722 (13.47%) participants in this sample had a lifetime history of
191 anxiety disorders, 65.92% ($n = 29,482$) of whom were female. Descriptive statistics for the full UK
192 Biobank and for the analytical samples stratified by sex and anxiety disorder status are presented in
193 Table 1 (physiological measures) and Supplement Table 4 (covariates).

Table 1. Physiological measures

	Overall ($N=502,521$)		Female		Male	
			Healthy control ($N=145,364$)	Anxiety disorder ($N=29,482$)	Healthy control ($N=141,992$)	Anxiety disorder ($N=15,240$)
	Mean (SD)	Missing	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
Hand-grip strength	31.77 (11.34)	3203	24.89 (6.48)	24.68 (6.64)	41.25 (9.11)	40.53 (9.22)
Systolic blood pressure	137.87 (18.65)	1325	135.71 (19.32)	133.23 (18.48)	141.28 (17.42)	139.63 (16.92)
Diastolic blood pressure	82.26 (10.15)	1323	80.70 (9.96)	80.29 (9.91)	84.22 (9.96)	83.92 (9.93)
Pulse rate	69.42 (11.26)	1323	69.87 (10.40)	70.33 (10.68)	67.76 (11.60)	68.66 (12.04)
Body mass index	27.43 (4.80)	3105	26.66 (4.85)	26.89 (5.20)	27.64 (4.02)	27.76 (4.33)
Body fat percentage	31.45 (8.55)	10408	36.06 (6.74)	36.40 (6.96)	24.97 (5.63)	25.27 (5.81)
Fat mass	24.86 (9.57)	10973	26.14 (9.50)	26.83 (10.23)	21.87 (7.88)	22.37 (8.48)
Fat-free mass	53.22 (11.50)	10176	44.33 (4.84)	44.62 (5.05)	63.67 (7.62)	63.80 (7.89)
Waist-hip ratio	0.87 (0.09)	2265	0.81 (0.07)	0.82 (0.07)	0.93 (0.06)	0.94 (0.06)
			$N=50,729$	$N=10,128$	$N=56,695$	$N=6,045$
Peak expiratory flow	407.82 (130.78)	168566	352.52 (76.81)	356.88 (77.84)	510.07 (115.61)	509.72 (115.63)
Forced expiratory volume 1s	2.85 (0.78)	149197	2.48 (0.53)	2.51 (0.53)	3.43 (0.74)	3.44 (0.74)
Forced vital capacity	3.78 (0.98)	149197	3.25 (0.64)	3.30 (0.65)	4.57 (0.88)	4.58 (0.89)
FEV ₁ / FVC	0.75 (0.07)	149197	0.76 (0.06)	0.76 (0.06)	0.75 (0.07)	0.75 (0.07)
			$N=101,279$	$N=19,217$	$N=97,749$	$N=10,076$
Heel bone mineral density	0.54 (0.14)	180831	0.52 (0.12)	0.52 (0.12)	0.58 (0.15)	0.57 (0.15)
			$N=45,320$	$N=10,630$	$N=46,549$	$N=5,459$
Arterial stiffness	9.34 (4.05)	332721	8.72 (4.27)	8.71 (3.33)	9.94 (4.59)	9.94 (2.92)

Note: SD = standard deviation; FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity.

194 Case-control differences

195 Case-control differences by sex are presented in Table 2. Females with anxiety disorders had a lower
196 hand-grip strength and blood pressure than healthy controls. Their pulse rate was elevated, and they had
197 higher values for all body composition measures and most lung function measures than controls. We
198 did not find evidence of differences in the FEV₁/FVC ratio, heel bone mineral density or arterial

199 stiffness. Male anxiety disorder cases had a lower hand-grip strength, blood pressure and heel bone
200 mineral density than healthy controls. Their pulse rate and all body composition measures were higher
201 than in controls, although the difference in fat-free mass did not survive multiple testing correction. We
202 did not find evidence of differences in lung function or arterial stiffness in males. The largest case-
203 control difference was observed for systolic blood pressure (SMD = -0.129, 95% CI -0.142 to -0.117,
204 $p_{\text{Bonf.}} < 0.001$ in females and SMD = -0.091, 95% CI -0.111 to -0.078, $p_{\text{Bonf.}} = 0.013$ in males).

Table 2. Differences in physiological measures between individuals with anxiety disorders and healthy controls

Variable	Female					Male				
	SMD	95% CI		$p_{\text{Bonf.}}$	p_{BH}	SMD	95% CI		$p_{\text{Bonf.}}$	p_{BH}
Hand-grip strength	-0.032	-0.044	-0.019	<0.001	<0.001	-0.079	-0.096	-0.062	<0.001	<0.001
Systolic blood pressure	-0.129	-0.142	-0.117	<0.001	<0.001	-0.095	-0.111	-0.078	<0.001	<0.001
Diastolic blood pressure	-0.041	-0.053	-0.028	<0.001	<0.001	-0.030	-0.046	-0.013	0.007	0.001
Pulse rate	0.045	0.032	0.057	<0.001	<0.001	0.078	0.061	0.095	<0.001	<0.001
Body mass index	0.047	0.035	0.060	<0.001	<0.001	0.029	0.013	0.046	0.017	0.002
Body fat percentage	0.050	0.038	0.063	<0.001	<0.001	0.054	0.037	0.070	<0.001	<0.001
Fat mass	0.071	0.059	0.084	<0.001	<0.001	0.063	0.046	0.080	<0.001	<0.001
Fat-free mass	0.058	0.046	0.071	<0.001	<0.001	0.017	0.000	0.034	0.831	0.083
Waist-hip ratio	0.044	0.031	0.056	<0.001	<0.001	0.091	0.074	0.107	<0.001	<0.001
Peak expiratory flow	0.057	0.035	0.078	<0.001	<0.001	-0.003	-0.029	0.024	>0.999	0.886
Forced expiratory volume 1s	0.064	0.042	0.085	<0.001	<0.001	0.010	-0.017	0.036	>0.999	0.582
Forced vital capacity	0.067	0.045	0.088	<0.001	<0.001	0.013	-0.013	0.040	>0.999	0.442
FEV ₁ / FVC	0.011	-0.010	0.033	>0.999	0.347	-0.005	-0.031	0.022	>0.999	0.844
Heel bone mineral density	-0.005	-0.021	0.010	>0.999	0.538	-0.067	-0.088	-0.047	<0.001	<0.001
Arterial stiffness	-0.003	-0.025	0.018	>0.999	0.712	-0.001	-0.029	0.027	>0.999	0.927

Note: SMD = standardised mean difference; CI = confidence interval; Bonf. = Bonferroni; BH = Benjamini & Hochberg; FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity. *P*-values for Welch's t-test. Negative values correspond to lower values in anxiety disorder cases.

205 *Chronic and/or severe anxiety*

206 Between 8.37% to 9.46% of female and 9.47% to 9.99% of male cases had chronic and/or severe anxiety
207 disorders ([Supplement Table 5](#)). In females, we observed the same overall pattern of results as in the
208 main analysis, although all observed differences were larger in magnitude. For example, the case-
209 control difference in body fat percentage was SMD = 0.113 (95% CI 0.074-0.151, $p_{\text{Bonf.}} < 0.001$)
210 ([Supplement Table 6](#)), compared to SMD = 0.050 (95% CI 0.038-0.063, $p_{\text{Bonf.}} < 0.001$) in the main
211 analysis. In male chronic and/or severe cases, we did not find evidence of a difference in diastolic blood
212 pressure compared to healthy controls (SMD = -0.013, 95% CI -0.064 to 0.038, $p_{\text{BH}} = 0.713$) and the
213 difference in body fat percentage was not statistically significant after multiple testing correction. For
214 most other physiological measures, we observed larger case-control differences than in the main
215 analysis ([Supplement Table 6](#)). For example, the case-control difference in systolic blood pressure was
216 SMD = -0.095 (95% CI -0.111 to -0.078, $p_{\text{Bonf.}} < 0.001$) in the main analysis and SMD = -0.153
217 (95% CI -0.204 to -0.102, $p_{\text{Bonf.}} < 0.001$) in this analysis.

218

219 *Anxiety without depression comorbidity*


220 After excluding anxiety disorder cases with depression comorbidity, we retained between 25.91% to
221 37.67% of female and 31.45% to 44.69% of male cases ([Supplementary Table 5](#)). In females,

222 differences in hand-grip strength, blood pressure, pulse rate and arterial stiffness remained statistically
223 significant but were smaller in magnitude than in the main analysis ([Supplement Table 7](#)). Body mass
224 index, fat mass and fat-free mass, which were higher in cases than in controls in the main analysis, were
225 lower in cases without depression comorbidity (SMDs between -0.026 and -0.049). We did not find
226 evidence of case-control differences in body fat percentage or waist-hip ratio in this analysis. There was
227 also no longer evidence of differences in lung function, except that the FEV₁/FVC ratio was lower in
228 cases than in controls (SMD = -0.048, 95% CI -0.082 to -0.013, $p_{BH} = 0.019$). Finally, heel bone
229 mineral density was lower in female cases (SMD = -0.036, 95% CI -0.060 to -0.012, $p_{Bonf.} = 0.043$).
230 In males, differences in hand-grip strength, blood pressure, pulse rate, waist-hip ratio, lung function,
231 heel bone mineral density and arterial stiffness were similar to the main analysis. Body mass index and
232 fat-free mass were lower in cases than in controls (SMD = -0.058, 95% CI -0.084 to -0.033, $p_{Bonf.} <$
233 0.001 and SMD = -0.066, 95% CI -0.092 to -0.041, $p_{Bonf.} < 0.001$, respectively) and we did not find
234 evidence of case-control differences in body fat percentage or fat mass, which were elevated in cases
235 in the main analysis.


236

237 **Case-control differences by age**

238 We found some evidence that age-related changes in blood pressure, pulse rate, body composition and
239 heel bone mineral density differed between female cases and controls ([Figure 1](#)). Systolic blood
240 pressure was -0.9 mmHg lower in cases at age 45 and this difference widened to -2.2 mmHg at age 65.
241 For diastolic blood pressure, we did not find evidence of case-control differences below age 52, and
242 slightly lower diastolic blood pressure in cases than in controls above age 52. Case-control differences
243 in pulse rate and body composition narrowed with age ([Supplement Figure 2](#)). Heel bone mineral
244 density was slightly lower in cases than in controls below age 55, and there was no evidence of
245 differences between older cases and controls.



246 In males, case-control differences in hand-grip strength, pulse rate, waist-hip ratio and heel bone
 247 mineral density narrowed with age (Figure 2 and Supplement Figure 3). There was some evidence
 248 that diastolic blood pressure was lower in cases than in controls above age 50, although the formal
 249 statistical test did not survive multiple testing correction. We found little evidence of case-control
 250 differences by age for the other physiological measures.



251 In females, we observed similar results across all physiological measures after adjustment for covariates
 252 (Supplement Figures 4 and 5). The formal statistical tests provided no evidence of case-control
 253 differences in age-related changes in heel bone mineral density, however, the overall pattern of results
 254 was comparable to the unadjusted model. In males, we also observed similar results in the adjusted
 255 model (Supplement Figures 6 and 7). Although the trajectories were similar to the unadjusted analysis,
 256 the formal statistical tests provided no evidence of case-control differences in age-related changes in

257 waist-hip ratio. The same was true for diastolic blood pressure and heel bone mineral density after
258 multiple testing correction.

259

260 *Chronic and/or severe anxiety*

261 In female chronic and/or severe cases, we observed similar results for age-related changes in blood
262 pressure and body composition, except that there was no evidence of case-control differences in fat-
263 free mass below age 45 ([Supplement Figures 8 and 9](#)). As in the main analysis, we observed no
264 evidence of case-control differences in age-related changes in lung function or arterial stiffness.
265 Differences in results were most evident for hand-grip strength and pulse rate, and to a lesser extent for
266 heel bone mineral density. The formal statistical tests provided some evidence of case-control
267 differences in age-related changes in blood pressure, body mass index, fat mass and fat-free mass,
268 although none survived multiple testing correction. For male chronic and/or severe cases, we found
269 some evidence that case-control differences in hand-grip strength and pulse rate narrowed with age,
270 similar to the results from the main analysis, although none of the formal statistical tests survived
271 multiple testing correction. There was less evidence of case-control differences in age-related changes
272 in systolic blood pressure and no evidence of case-control differences in age-related changes in diastolic
273 blood pressure. For all other physiology measures, none of the formal statistical tests were statistically
274 significant ([Supplement Figures 10 and 11](#)).

275

276 *Anxiety without depression comorbidity*

277 In female cases without depression comorbidity, none of the formal statistical tests provided evidence
278 of case-control differences in age-related changes in physiology. We also observed less evidence of
279 differences by age in blood pressure or pulse rate. There was some evidence that several body
280 composition and lung function measures were lower in cases than in controls between ages 45 to 65
281 ([Supplement Figures 12 and 13](#)). In male cases, the formal statistical test provided some evidence of
282 case-control differences in age-related changes in pulse rate, although it did not survive multiple testing
283 correction. None of the other formal statistical tests were statistically significant and there was less
284 evidence of case-control differences in age-related physiological changes ([Supplement Figures 14 and](#)
285 [15](#)).

286

287 **Additional sensitivity analyses**

288 Case-control differences in cardiovascular function by age were similar to the results of our main
289 analysis after additional adjustment for BMI ([Supplement Figures 16 and 17](#)). Excluding anxiety
290 disorder cases who reported current use of antidepressants ($n = 6517$ females and $n = 2700$ males)
291 had a negligible effect on case-control differences in blood pressure ([Supplement Table 7](#)).

292 **Discussion**

293

294 **Principal findings**

295 We observed case-control differences in hand-grip strength, blood pressure, pulse rate and body
296 composition in both sexes, while case-control differences in lung function and heel bone mineral density
297 were specific to females and males, respectively. We found no evidence of case-control differences in
298 arterial stiffness.

299

300 Most of the observed differences were larger when we examined chronic and/or severe anxiety
301 disorders. However, in males, the difference in diastolic blood pressure was smaller and not statistically
302 significant, and differences in body fat percentage and heel bone mineral density, while similar in
303 magnitude, were no longer statistically significant.

304

305 After excluding cases with comorbid depression, most differences remained statistically significant but
306 were smaller in magnitude. However, body composition measures in both sexes were either lower in
307 cases, or we did not find evidence of case-control differences. We found some evidence that heel bone
308 mineral density was lower in female cases without comorbid depression. Most case-control differences
309 in lung function, however, were no longer statistically significant. We also did not find evidence of
310 case-control differences in diastolic blood pressure in males without comorbid depression.

311

312 Differences in age-related physiological changes between female anxiety disorder cases and healthy
313 controls were most evident for blood pressure, pulse rate and body composition, with some evidence of
314 differences in heel bone mineral density. Most case-control differences narrowed with age, except that
315 we found a larger difference in blood pressure in older participants. In males, case-control differences
316 in hand-grip strength, pulse rate, and to a lesser extent in waist-hip ratio and heel bone mineral density
317 narrowed with age. Diastolic blood pressure was lower in older cases than in controls.

318

319 The overall pattern of results was comparable in female chronic and/or severe cases, but there was
320 generally less evidence of differences between trajectories in males. Except for body composition, there
321 was limited evidence of case-control differences in age-related physiological changes after excluding
322 individuals with comorbid depression.

323

324 **Findings in context**

325 Consistent with findings from the Netherland Study of Depression and Anxiety (NESDA)(12), female
326 cases had a lower hand-grip strength. Hand-grip strength was also lower in male cases, which had not
327 been observed in the NESDA.

328

329 Previous findings regarding anxiety disorders and blood pressure have been mixed and studies have
330 often examined hypertension instead of blood pressure(30-33). While a recent meta-analysis reported
331 increased rates of hypertension in anxiety disorders(14), several studies found no statistically significant
332 associations with hypertension or blood pressure(34-38). Some studies observed lower blood pressure
333 in anxiety disorders(39-41). Antidepressant medication and benzodiazepine use may affect blood
334 pressure(42-44), and some population-based studies have observed lower blood pressure in
335 depression(16, 42). The high degree of comorbidity between anxiety disorders and depression and
336 differences in medication use might partially explain these mixed results. We observed lower blood
337 pressure in anxiety disorders, except for diastolic blood pressure in males, irrespective of depressive
338 comorbidity. Excluding individuals who reported antidepressant use at baseline resulted in a negligible
339 decrease in the case-control difference in systolic blood pressure and a negligible increase in the
340 difference in diastolic blood pressure. Case-control differences in blood pressure were larger in chronic
341 and/or severe anxiety disorders.

342

343 Consistent with previous research(45, 46), we observed a higher pulse rate in anxiety disorder cases.
344 Noteworthy, reductions in anxiety disorder severity following cognitive behavioural therapy have been
345 associated with a decrease in resting pulse rate(47).

346

347 Previous research has found higher rates of obesity(48, 49) and poor diet(50) in anxiety disorders,
348 consistent with our observation that cases had elevated measures of body composition. However, our
349 analyses suggested that these differences may be modified by depression comorbidity. Depression has
350 been associated with increased metabolic risk factors(51) and elevated body composition measures(16).
351 One study found that depression, but not anxiety disorders, was associated with an increased risk of
352 metabolic syndrome(52), although a large Finnish birth cohort study found no evidence that either
353 depression or anxiety disorders were associated with metabolic syndrome(53).

354

355 Our lung function results contradict previous research. A cross-sectional analysis of the NESDA found
356 poorer lung function in females with anxiety disorders and/or depression compared to healthy controls
357 and better lung function in male cases than in controls(54). A 6-year longitudinal assessment of these
358 participants suggested a greater decline in lung function in male cases compared to controls(12). We
359 observed better lung function in female cases and found no statistically significant case-control
360 differences in males. However, we observed no evidence of differences after excluding individuals with
361 comorbid depression. Noteworthy, the results from the NESDA were not reported separately for anxiety
362 disorders and depression.

363

364 Our results confirm previous research(55) that found a lower bone mineral density in male cases and
365 limited evidence of a case-control difference in females.

366

367 We did not observe any differences in arterial stiffness between cases and controls. This finding is
368 surprising given that previous studies have reported increased arterial stiffness in anxiety disorders(56,
369 57).

370

371 Inconsistencies in findings between studies could result from differences in sample characteristics such
372 as age, sex, severity of symptoms or the prevalence of effect modifiers. Systematic reviews of studies
373 examining each measure of physiological function in relation to anxiety disorders could address these
374 important questions. The definition of anxiety disorders, including which specific diagnoses were
375 included, might also contribute to differences in results.

376

377 To our knowledge, we report the first study of age-related changes in physiology in anxiety disorders
378 with age as a continuous rather than a categorical variable. Previous studies dichotomised age, for
379 example testing differences between middle-aged participants and others(14), making comparisons
380 with our study difficult.

381

382 **Mechanisms**

383 Several mechanisms could explain the physiological differences between anxiety disorders cases and
384 healthy controls. Anxiety disorders are sometimes associated with less healthy lifestyle behaviours(58)
385 which could affect a range of physiological makers. Physiological differences could also reflect the
386 cumulative effects of anxiety-related overactivation of the hypothalamic-pituitary-adrenal axis and
387 sympathetic nervous system(33) as well as increased inflammation and oxidative stress(59-61). It is
388 also possible that the reciprocal relationship between late-life anxiety and associated cognitive
389 impairment may be a driver of poor physiological function(62). The greater case-control differences
390 observed in chronic and/or severe anxiety disorders could be explained by a dose-response relationship
391 between severity of symptoms and physiology mediated by a greater impact of anxiety on lifestyle,
392 overactivation of the sympathetic nervous system and other potential pathways. A potential explanation
393 for the observation that case-control differences decreased with increasing age is that the prevalence of
394 comorbidities increases with age which may dilute the effects that anxiety disorders may have.

395

396 **Limitations**

397 The cross-sectional study design presents uncertainty about whether case-control differences by age
398 represent changes due to ageing or potential cohort effects. Future work should examine physiological
399 function in anxiety disorders longitudinally. Although we found that all physiological measures varied
400 by age, selection bias resulting in healthier older adults participating at higher rates relative to their age

401 group could result in the underestimation of age-related changes. To achieve maximum cohort
402 coverage, we identified cases from multiple data sources, with strengths and limitations that have been
403 discussed elsewhere(23, 63, 64). For the primary care records, we included the additional quality control
404 criterion that cases needed to have at least two mentions of anxiety in their records. Anxiety disorder
405 cases in this study also included individuals with a single episode. This likely resulted in an
406 underestimation of case-control differences. A small number of individuals with subthreshold disorders
407 could be present amongst the healthy controls, which could have attenuated observed differences. We
408 examined a transdiagnostic definition of anxiety disorders, and differences in physiological function
409 between specific diagnoses could be explored in future studies. Although we found that the differences
410 between individuals with chronic and/or severe anxiety disorders and controls were larger, these
411 differences could at least partly reflect higher levels of comorbidities in addition to the effects of
412 chronicity and/or severity. Some caution is warranted in interpreting the findings of the sensitivity
413 analyses due to the smaller sample size and lower statistical power. Finally, limitations in the
414 assessment of physiological function may have masked some differences between cases and controls.
415 For example, dynamic measures such as pulse rate were not measured longitudinally, and our study
416 does therefore not provide insights into potential case-control differences that could be identified from
417 time-series data. Similarly, lung function was estimated through volumetric measures using breath
418 spirometry and we could therefore not examine irregularity of respiratory patterns. Physiological
419 measures with higher temporal resolution could be examined in future studies.

420

421 **Generalisability**

422 UK Biobank participants are not fully representative of the UK population. MHQ respondents were
423 also more educated, of higher socioeconomic status and had fewer long-standing illnesses than
424 participants who did not complete the MHQ. Similar patterns of disease prevalence were present in the
425 MHQ and hospital inpatient records, although anxiety was reported more frequently in the MHQ(18).
426 Nevertheless, the overall number of individuals with a lifetime history of anxiety disorders identified
427 in our study was comparable to previous epidemiological studies(65). Wider issues of generalisability
428 of findings from the UK Biobank have been discussed elsewhere(66). Our findings do not generalise to
429 populations below age 40 or older than age 70, and there was greater uncertainty near the lower and
430 upper extremes of the age range in this study. Additional studies in younger participants and in the
431 elderly are needed.

432

433 **Implications**

434 Individuals with a lifetime history of anxiety disorders differed from healthy controls across multiple
435 physiological measures, with some evidence of case-control differences by age. The differences
436 observed varied by chronicity/severity and depression comorbidity. Monitoring of physiological

437 function in individuals with anxiety disorders should be adapted depending on depression comorbidity
438 status.

439 **Ethics**

440 We assert that all procedures contributing to this work comply with the ethical standards of the relevant
441 national and institutional committees on human experimentation. All procedures were approved for the
442 UK Biobank study by the National Information Governance Board for Health and Social Care and the
443 NHS North West Multicentre Research Ethics Committee (11/NW/0382). No project-specific ethical
444 approval is needed. Data access permission has been granted under UK Biobank application 45514.
445 Written informed consent was obtained from all participants.

446

447 **Declaration of Interest**

448 JM receives studentship funding from the Biotechnology and Biological Sciences Research Council
449 (BBSRC) and Eli Lilly and Company Limited. CML is a member of the Scientific Advisory Board of
450 Myriad Neuroscience. CF has been a speaker for Janssen. THH declares no relevant conflict of interest.

451

452 **Funding**

453 JM receives studentship funding from the Biotechnology and Biological Sciences Research Council
454 (BBSRC) (ref: 2050702) and Eli Lilly and Company Limited. CF was supported by Fondazione
455 Umberto Veronesi (<https://www.fondazioneveronesi.it>). CML is part-funded by the National Institute
456 for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley
457 NHS Foundation Trust and King's College London. The views expressed are those of the authors and
458 not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

459

460 **Acknowledgments**

461 This research has been conducted using data from UK Biobank, a major biomedical database. This
462 project made use of time on Rosalind HPC, funded by Guy's & St Thomas' Hospital NHS Trust
463 Biomedical Research Centre (GSTT-BRC), South London & Maudsley NHS Trust Biomedical
464 Research Centre (SLAM-BRC), and Faculty of Natural Mathematics & Science (NMS) at King's
465 College London.

466

467 **Author Contribution**

468 CML acquired the studentship funding, interpreted the findings and critically reviewed the manuscript.
469 JM conceived the idea of the study, acquired the data, carried out the statistical analysis, interpreted the
470 findings, wrote the manuscript and revised the manuscript for final submission. THH contributed to the
471 study design, interpreted the findings and contributed to the writing of the manuscript. CF interpreted
472 the findings and critically reviewed the manuscript. All authors read and approved the final manuscript.
473 JM had full access to all data used in this study and takes responsibility for the integrity of the data and
474 the accuracy of the data analysis.

475

476 **Data Availability**

477 The data used are available to all bona fide researchers for health-related research that is in the public
478 interest, subject to an application process and approval criteria. Study materials are publicly available
479 online at <http://www.ukbiobank.ac.uk>.

480 References

481

- 482 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369
483 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global
484 Burden of Disease Study 2019. *The Lancet*. 2020;396(10258):1204-22.
- 485 2. Baxter AJ, Scott K, Vos T, Whiteford H. Global prevalence of anxiety disorders: a systematic
486 review and meta-regression. *Psychological Medicine*. 2013;43(5):897-910.
- 487 3. Hovenkamp-Hermelink JH, Jeronimus BF, Myroniuk S, Riese H, Schoevers RA. Predictors
488 of persistence of anxiety disorders across the lifespan: a systematic review. *The Lancet Psychiatry*.
489 2021;8(5):428-43.
- 490 4. Markkula N, Härkänen T, Perälä J, Partti K, Pena S, Koskinen S, et al. Mortality in people
491 with depressive, anxiety and alcohol use disorders in Finland. *The British Journal of Psychiatry*.
492 2012;200(2):143-9.
- 493 5. Meier SM, Mattheisen M, Mors O, Mortensen PB, Laursen TM, Penninx BW. Increased
494 mortality among people with anxiety disorders: total population study. *The British Journal of*
495 *Psychiatry*. 2016;209(3):216-21.
- 496 6. Perna G, Iannone G, Alciati A, Caldirola D. Are anxiety disorders associated with accelerated
497 aging? A focus on neuroprogression. *Neural Plasticity*. 2016;2016.
- 498 7. Karim HT, Ly M, Yu G, Krafty R, Tudorascu DL, Aizenstein HJ, et al. Aging faster: worry
499 and rumination in late life are associated with greater brain age. *Neurobiology of Aging*. 2021;101:13-
500 21.
- 501 8. Malouff JM, Schutte NS. A meta-analysis of the relationship between anxiety and telomere
502 length. *Anxiety, Stress, & Coping*. 2017;30(3):264-72.
- 503 9. Verhoeven JE, Révész D, van Oppen P, Epel ES, Wolkowitz OM, Penninx BW. Anxiety
504 disorders and accelerated cellular ageing. *The British Journal of Psychiatry*. 2015;206(5):371-8.
- 505 10. Brenes GA, Guralnik JM, Williamson JD, Fried LP, Simpson C, Simonsick EM, et al. The
506 influence of anxiety on the progression of disability. *Journal of the American Geriatrics Society*.
507 2005;53(1):34-9.
- 508 11. Brenes GA, Penninx BW, Judd PH, Rockwell E, Sewell DD, Wetherell JL. Anxiety,
509 depression and disability across the lifespan. *Aging and Mental Health*. 2008;12(1):158-63.
- 510 12. Lever-van Milligen BA, Lamers F, Smit JH, Penninx BW. Six-year trajectory of objective
511 physical function in persons with depressive and anxiety disorders. *Depression and Anxiety*.
512 2017;34(2):188-97.
- 513 13. Goodwin RD, Chuang S, Simuro N, Davies M, Pine DS. Association between lung function
514 and mental health problems among adults in the United States: findings from the First National Health
515 and Nutrition Examination Survey. *American Journal of Epidemiology*. 2007;165(4):383-8.
- 516 14. Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and
517 hypertension: a systematic review and meta-analysis of epidemiological studies. *Neuropsychiatric*
518 *Disease and Treatment*. 2015;11:1121-30.
- 519 15. Austad SN, Bartke A. Sex differences in longevity and in responses to anti-aging
520 interventions: a mini-review. *Gerontology*. 2016;62(1):40-6.
- 521 16. Mutz J, Lewis CM. Lifetime depression and age-related changes in body composition,
522 cardiovascular function, grip strength and lung function: sex-specific analyses in the UK Biobank.
523 *Aging*. 2021;13(13):17038-79.
- 524 17. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
525 resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-9.
- 526 18. Davis KA, Coleman JR, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in UK
527 Biobank—development, implementation and results from an online questionnaire completed by 157
528 366 participants: a reanalysis. *BJPsych Open*. 2020;6(2):E18.
- 529 19. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-
530 7 and GAD-2: a systematic review and diagnostic metaanalysis. *General Hospital Psychiatry*.
531 2016;39:24-31.

- 532 20. Fabbri C, Hageaars SP, John C, Williams AT, Shrine N, Moles L, et al. Genetic and clinical
533 characteristics of treatment-resistant depression using primary care records in two UK cohorts.
534 *Molecular Psychiatry*. 2021.
- 535 21. Stubbs B, Koyanagi A, Veronese N, Vancampfort D, Solmi M, Gaughran F, et al. Physical
536 multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people
537 across 48 low-and middle-income countries. *BMC Medicine*. 2016;14(1):1-12.
- 538 22. Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in bipolar
539 disorder and undertreatment of cardiovascular disease: a cross sectional study. *BMC Medicine*.
540 2013;11(1):1-11.
- 541 23. Davis KA, Cullen B, Adams M, Brailean A, Breen G, Coleman JR, et al. Indicators of mental
542 disorders in UK Biobank—A comparison of approaches. *International Journal of Methods in*
543 *Psychiatric Research*. 2019;28(3):e1796.
- 544 24. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and
545 characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional
546 study of 172,751 participants. *PloS One*. 2013;8(11):e75362.
- 547 25. Mutz J, Young AH, Lewis CM. Age-related changes in physiology in individuals with bipolar
548 disorder. *Journal of Affective Disorders*. 2021.
- 549 26. Guggenheim JA, Williams C. Childhood febrile illness and the risk of myopia in UK Biobank
550 participants. *Eye*. 2016;30(4):608-14.
- 551 27. Mutz J, Roscoe CJ, Lewis CM. Exploring health in the UK Biobank: associations with
552 sociodemographic characteristics, psychosocial factors, lifestyle and environmental exposures. *BMC*
553 *Medicine*. 2021;19(1):240.
- 554 28. Wood SN. *Generalized additive models: an introduction with R*: CRC press; 2017.
- 555 29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful
556 approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Methodological)*.
557 1995;57(1):289-300.
- 558 30. Byrd JB, Brook RD. Anxiety in the “age of hypertension”. *Current Hypertension Reports*.
559 2014;16(10):1-7.
- 560 31. Cuffee Y, Ogedegbe C, Williams NJ, Ogedegbe G, Schoenthaler A. Psychosocial risk factors
561 for hypertension: an update of the literature. *Current Hypertension Reports*. 2014;16(10):483.
- 562 32. Player MS, Peterson LE. Anxiety disorders, hypertension, and cardiovascular risk: a review.
563 *The International Journal of Psychiatry in Medicine*. 2011;41(4):365-77.
- 564 33. Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety,
565 and cardiovascular disease. *American Journal of Hypertension*. 2015;28(11):1295-302.
- 566 34. Jackson CA, Pathirana T, Gardiner PA. Depression, anxiety and risk of hypertension in mid-
567 aged women: a prospective longitudinal study. *Journal of Hypertension*. 2016;34(10):1959-66.
- 568 35. Jones-Webb R, Jacobs Jr DR, Flack JM, Liu K. Relationships between depressive symptoms,
569 anxiety, alcohol consumption, and blood pressure: results from the CARDIA study. *Alcoholism:*
570 *Clinical and Experimental Research*. 1996;20(3):420-7.
- 571 36. Maatouk I, Herzog W, Böhlen F, Quinzler R, Löwe B, Saum K-U, et al. Association of
572 hypertension with depression and generalized anxiety symptoms in a large population-based sample
573 of older adults. *Journal of Hypertension*. 2016;34(9):1711-20.
- 574 37. Shinn EH, Poston WSC, Kimball KT, St. Jeor ST, Foreyt JP. Blood pressure and symptoms
575 of depression and anxiety: a prospective study. *American Journal of Hypertension*. 2001;14(7):660-4.
- 576 38. Yan LL, Liu K, Matthews KA, Daviglius ML, Ferguson TF, Kiefe CI. Psychosocial factors
577 and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study.
578 *JAMA*. 2003;290(16):2138-48.
- 579 39. Huang Y, Su Y, Jiang Y, Zhu M. Sex differences in the associations between blood pressure
580 and anxiety and depression scores in a middle-aged and elderly population: the Irish Longitudinal
581 Study on Ageing (TILDA). *Journal of Affective Disorders*. 2020;274:118-25.
- 582 40. Hildrum B, Romild U, Holmen J. Anxiety and depression lowers blood pressure: 22-year
583 follow-up of the population based HUNT study, Norway. *BMC Public health*. 2011;11(1):1-8.
- 584 41. Bhat SK, Beilin LJ, Robinson M, Burrows S, Mori TA. Relationships between depression and
585 anxiety symptoms scores and blood pressure in young adults. *Journal of Hypertension*.
586 2017;35(10):1983-91.

- 587 42. Licht CM, De Geus EJ, Seldenrijk A, Van Hout HP, Zitman FG, Van Dyck R, et al.
588 Depression is associated with decreased blood pressure, but antidepressant use increases the risk for
589 hypertension. *Hypertension*. 2009;53(4):631-8.
- 590 43. Zhong Z, Wang L, Wen X, Liu Y, Fan Y, Liu Z. A meta-analysis of effects of selective
591 serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and
592 serotonin and noradrenaline reuptake inhibitor controlled trials. *Neuropsychiatric Disease and
593 Treatment*. 2017;13:2781-96.
- 594 44. Mendelson N, Gontmacher B, Vodonos A, Novack V, Abu-Ajaj M, Wolak A, et al.
595 Benzodiazepine consumption is associated with lower blood pressure in ambulatory blood pressure
596 monitoring (ABPM): retrospective analysis of 4938 ABPMs. *American Journal of Hypertension*.
597 2018;31(4):431-7.
- 598 45. Latvala A, Kuja-Halkola R, Rück C, D'Onofrio BM, Jernberg T, Almqvist C, et al.
599 Association of resting heart rate and blood pressure in late adolescence with subsequent mental
600 disorders: a longitudinal population study of more than 1 million men in Sweden. *JAMA Psychiatry*.
601 2016;73(12):1268-75.
- 602 46. Thayer JF, Friedman BH, Borkovec TD. Autonomic characteristics of generalized anxiety
603 disorder and worry. *Biological Psychiatry*. 1996;39(4):255-66.
- 604 47. Gonçalves R, Rodrigues H, Novaes F, Arbol J, Volchan E, Coutinho ESF, et al. Listening to
605 the heart: a meta-analysis of cognitive behavior therapy impact on the heart rate of patients with
606 anxiety disorders. *Journal of Affective Disorders*. 2015;172:231-40.
- 607 48. Garipey G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the
608 population: a systematic review and meta-analysis. *International Journal of Obesity*. 2010;34(3):407-
609 19.
- 610 49. Barry D, Pietrzak RH, Petry NM. Gender differences in associations between body mass
611 index and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on
612 Alcohol and Related Conditions. *Annals of Epidemiology*. 2008;18(6):458-66.
- 613 50. Gibson-Smith D, Bot M, Brouwer IA, Visser M, Penninx BW. Diet quality in persons with
614 and without depressive and anxiety disorders. *Journal of Psychiatric Research*. 2018;106:1-7.
- 615 51. McCaffery JM, Niaura R, Todaro JF, Swan GE, Carmelli D. Depressive symptoms and
616 metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin
617 study. *Psychosomatic Medicine*. 2003;65(3):490-7.
- 618 52. Skilton MR, Moulin P, Terra J-L, Bonnet F. Associations between anxiety, depression, and
619 the metabolic syndrome. *Biological Psychiatry*. 2007;62(11):1251-7.
- 620 53. Herva A, Räsänen P, Miettunen J, Timonen M, Läksy K, Veijola J, et al. Co-occurrence of
621 metabolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 Birth
622 Cohort Study. *Psychosomatic Medicine*. 2006;68(2):213-6.
- 623 54. van Milligen BA, Lamers F, Guus T, Smit JH, Penninx BW. Objective physical functioning
624 in patients with depressive and/or anxiety disorders. *Journal of Affective Disorders*. 2011;131(1-
625 3):193-9.
- 626 55. Williams LJ, Pasco JA, Jacka FN, Hodge JM, Kotowicz MA, Berk M. Quantitative Heel
627 Ultrasound (QUS) measures of bone quality in association with mood and anxiety disorders. *Journal
628 of Affective Disorders*. 2013;146(3):395-400.
- 629 56. Seldenrijk A, van Hout HP, van Marwijk HW, de Groot E, Gort J, Rustemeijer C, et al.
630 Depression, anxiety, and arterial stiffness. *Biological Psychiatry*. 2011;69(8):795-803.
- 631 57. Yeragani VK, Kumar R, Bar KJ, Chokka P, Tancer M. Exaggerated differences in pulse wave
632 velocity between left and right sides among patients with anxiety disorders and cardiovascular
633 disease. *Psychosomatic Medicine*. 2007;69(8):717-22.
- 634 58. Bonnet F, Irving K, Terra J-L, Nony P, Berthezène F, Moulin P. Anxiety and depression are
635 associated with unhealthy lifestyle in patients at risk of cardiovascular disease. *Atherosclerosis*.
636 2005;178(2):339-44.
- 637 59. Vogelzangs N, Beekman A, De Jonge P, Penninx B. Anxiety disorders and inflammation in a
638 large adult cohort. *Translational Psychiatry*. 2013;3(4):e249-e.
- 639 60. Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in fear-and
640 anxiety-based disorders: PTSD, GAD, and beyond. *Neuropsychopharmacology*. 2017;42(1):254-70.

- 641 61. Black C, Bot M, Scheffer P, Penninx B. Oxidative stress in major depressive and anxiety
642 disorders, and the association with antidepressant use; results from a large adult cohort. *Psychological*
643 *Medicine*. 2017;47(5):936-48.
- 644 62. Beaudreau SA, O'Hara R. Late-life anxiety and cognitive impairment: a review. *The*
645 *American Journal of Geriatric Psychiatry*. 2008;16(10):790-803.
- 646 63. Davis K, Hotopf M. Mental health phenotyping in UK Biobank. *Progress in Neurology and*
647 *Psychiatry*. 2019;23(1):4-7.
- 648 64. Glanville KP, Coleman JR, Howard DM, Pain O, Hanscombe KB, Jermy B, et al. Multiple
649 measures of depression to enhance validity of Major Depressive Disorder in the UK Biobank.
650 *BJPsych Open*. 2021;7(2):e44.
- 651 65. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. *Dialogues*
652 *Clin Neurosci*. 2015;17(3):327-35.
- 653 66. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
654 sociodemographic and health-related characteristics of UK Biobank participants with those of the
655 general population. *American Journal of Epidemiology*. 2017;186(9):1026-34.
656